• Amgen and CytomX Therapeutics Announce Partnership for Immuno-Oncology Research
  • $215 Million Public-Private Partnership Formed to Fight Cancer
  • FDA Grants Priority Review to Application for Opdivo as Treatment for Resected Advanced Melanoma
  • SCLC Patients with High Tumor Mutation Burden Show Promising Responses to Opdivo Alone or with Yervoy
  • Large-scale Collaborative Effort Aims to Increase Understanding of Cancer Therapy Combinations
  • Presage Biosciences Awarded Grant to Develop CIVO Microdosing Platform Used Inside Tumors
  • Imlygic-Yervoy Combo Twice as Effective as Yervoy in Fighting Melanoma, Study Finds
  • Microsatellite Stable Colorectal Cancer Dosing Begins in Phase 2 Trial of Combo Therapy
  • EMA to Review Marketing Application for Imfinzi as NSCLC Treatment
  • SELLAS and Merck Plan Phase 1/2 Trial of Galinpepimut-S and Keytruda in Five Cancers
  • FDA Approves Quicker L-DOS47 Dose Escalation in Phase 1 Lung Cancer Trial
  • MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors